Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 09, 2023 07:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics Announces Collaboration with Cabaletta Bio for Use of Autolus’ Safety Switch System in Cell Therapies for Autoimmune Disease

LONDON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces...
December 21, 2022 16:01 ET | Source: Autolus Therapeutics plc

Autolus Announces Partial Exercise of Underwriters' Option to Purchase Additional ADSs

LONDON, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced today...
December 12, 2022 10:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2022

Obe-cel: 35% of relapsed/refractory adult B-ALL patients in the ALLCAR19 trial remain in complete remission at a median follow up of three years without the need for additional anti-leukemia...
December 08, 2022 21:11 ET | Source: Autolus Therapeutics plc

Autolus Announces Pricing of Public Offering

LONDON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
December 08, 2022 16:03 ET | Source: Autolus Therapeutics plc

Autolus Announces Proposed Public Offering in the United States

LONDON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
December 08, 2022 16:02 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics to Receive $70 Million in Milestone Payments from Blackstone Life Sciences

Development milestone of $35m achieved earlier than anticipated as a result of the positive interim analysis of Autolus’ pivotal FELIX Phase 2 trial, announced in a separate press release...
December 08, 2022 16:01 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics announces pivotal Phase 2 FELIX clinical trial has met primary endpoint at interim analysis

Obe-cel demonstrated Overall Remission Rate (ORR) of 70% in interim analysis of 50 patients with relapsed/refractory (r/r) adult Acute Lymphoblastic Leukemia (ALL)Encouraging safety data observed,...
November 30, 2022 07:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics announces handover of first clean rooms of new Stevenage, UK, manufacturing facility

LONDON, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces...
November 03, 2022 09:31 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics to Present Three Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2022

obe-cel: poster presentation in B-ALL and B-NHL patientsAUTO1/22: poster presentation in pediatric ALL patientsAUTO4: poster presentation in T-Cell Lymphoma patients LONDON, Nov. 03, 2022 ...
November 03, 2022 07:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics Reports Third Quarter 2022 Financial Results and Operational Progress

Pivotal FELIX Phase 2 clinical trial of obe-cel in relapsed/refractory (r/r) Acute Lymphoblastic Leukemia (ALL) on track for Q4 2022 updateCommercial manufacturing site build on schedule for handover...